Afraxis, Inc Revenue

Biotechnology Research • San Diego, California, United States • 1-10 Employees

Afraxis, Inc revenue & valuation

Annual revenue	$3,000,000
Revenue per employee	$750,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$9,600,000
Total funding	$300,000

Key Contact at Afraxis, Inc

Sergio Duron

Director, Medicinal Chemistry

Company overview

Headquarters	6605 Nancy Ridge Rd. Ste 224, San Diego, CA 92121, US
Phone number	+18584361539
Website	afraxis.com
SIC	873
Keywords	CNS, Neurotoxicity, In Vitro Preclinical Efficacy, In Vivo Preclinical Efficacy, Structure-Efficacy Relationships (Ser)
Founded	2013
Employees	1-10
Socials

About Afraxis, Inc

Afraxis Inc. is a contract research organization (CRO) specializing in: - CNS preclinical efficacy evaluations (in vivo & in vitro) - Neurotoxicity evaluations - Structure-Efficacy Relationship (SER) medicinal chemistry The patented Afraxis ESP (Enhanced Spine Platform) technology produces a rapid, high-information read-out of synaptic networks from whole brain or other tissue preparations. The process incorporates (a) specialized labeling of individual neurons, (b) laser-scanning microscopy, (c) rapid and high-detail morphometry of individual synapses, and (d) novel powerful statistical methods tailored for big data analyses. The Afraxis ESP platform was first developed within the original Afraxis, Inc. (now Afraxis Holdings), a company founded in 2007 to develop novel therapeutics for Fragile-X Syndrome (FXS) based on the work of Nobel laureate Susumu Tonegawa. The ESP technology was developed originally to solve an unmet need in Fragile-X drug discovery: the lack of a rapid tool to evaluate test compounds against dendritic spine abnormalities, the hallmark neuorbiological phenotype of FXS observed in both humans and rodent models. Considering the broad reach of dendritic spine abnormalitiies throughout CNS diseases, the tool was immediately applicable for other indications. The current Afraxis, Inc. was founded in April 2013 as a spin-out company by Christopher Rex and Carmine Stengone to develop the core ESP technology and drug discovery services.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Director

Funding Data

Explore Afraxis, Inc's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2012-01-21	12	$300,000

Funding Insights

$300,000

Total funding amount

$300,000

Most recent funding amount

Number of funding rounds

Afraxis, Inc Tech Stack

Discover the technologies and tools that power Afraxis, Inc's digital infrastructure, from frameworks to analytics platforms.

Cloudflare

CDN

Google Workspace

HTTP/3

Miscellaneous

MailChimp

Zendesk

Documentation

Frequently asked questions

Afraxis, Inc is located in San Diego, California, US.

You can reach Afraxis, Inc at +18584361539.

Afraxis, Inc generates an estimated annual revenue of $3,000,000. This revenue figure reflects the company's market position and business performance in its industry.

Afraxis, Inc has an estimated valuation of $9,600,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Afraxis, Inc was founded in 2013, making it 13 years old. The company has established itself as a significant player in its industry over this time.

Afraxis, Inc has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Afraxis, Inc has raised a total of $300,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contact at Afraxis, Inc

Sergio Duron

Director, Medicinal Chemistry

4.8

40,000 users